Claims for Patent: 7,763,582

Summary for Patent: 7,763,582

Title:	Localized insulin delivery for bone healing
Abstract:	A method of promoting bone healing in a non-diabetic patient in need thereof by locally administering a therapeutically effective amount of insulin to the patient. A drug delivery device, which includes insulin and a pharmaceutically acceptable carrier, wherein the device is adapted for localized administration of insulin to a patient in need thereof is also presented.
Inventor(s):	Lin; Sheldon Suton (Chatham, NJ), Gandhi; Ankur (Metuchen, NJ), O\'Connor; James Patrick (Fanwood, NJ), Al-Zube; Loay A. (Zarga, JO), Benevenia; Joseph (Montclair, NJ), Parsons; J. Russell (Perth Amboy, NJ)
Assignee:	University of Medicine and Dentistry Of New Jersey (New Brunswick, NJ)
Application Number:	12/280,085
Patent Claims:	1. A method of promoting bone healing in a non-diabetic patient in need thereof comprising locally administering a therapeutically effective amount of insulin to said patient. 2. The method of claim 1, wherein said insulin is delivered via an insulin delivery system. 3. The method of claim 1, wherein said patient is afflicted with a bone condition selected from the group consisting of bone fracture, bone trauma, arthrodesis, and a bone deficit condition associated with post-traumatic bone surgery, post-prosthetic joint surgery, post-plastic bone surgery, post-dental surgery, bone chemotherapy treatment, congenital bone loss, post traumatic bone loss, post surgical bone loss, post infectious bone loss, allograft incorporation or bone radiotherapy treatment. 4. The method of claim 1, wherein said insulin is selected from the group consisting of regular insulin, isophane insulin, neutral protamine hagedorn (NPH) insulin, semilente insulin, lente insulin, ultralente insulin, insulin glargine, insulin lispro, and insulin aspart. 5. The method of claim 1, wherein said insulin delivery system comprises at least one biocompatible carrier. 6. The method of claim 5, wherein said biocompatible carrier comprises poly-lactic acid, poly-glycolic acid, copolymers of poly-lactic acid or poly-glycolic acid. 7. The method of claim 5, wherein said biocompatible carrier comprises at least one bioerodible fatty acid or a metal salt of a fatty acid. 8. The method of claim 7, wherein said fatty acid is selected from the group consisting of palmitic acid, steric acid, oleic acid, myristic acid, and metal salts thereof. 9. The method of claim 5, wherein said carrier comprises porous or non-porous calcium phosphate, porous or non-porous hydroxyapatite, porous or non-porous tricalcium phosphate, porous or non-porous tetracalcium phosphate, porous or non-porous calcium sulfate, or a combination thereof. 10. The method of claim 2, wherein said insulin delivery system comprises an article for implantation. 11. The method of claim 1, wherein said insulin delivery system comprises a coating on an article for implantation. 12. The method of claim 1, wherein said insulin delivery system comprises a bioactive bone agent. 13. The method of claim 12, wherein said method further comprises contacting the site of desired bone healing with a therapeutically effective amount of a bioactive bone agent selected from the group consisting of peptide growth factors, anti-inflammatory factors, pro-inflammatory factors, inhibitors of apoptosis, MMP inhibitors and bone catabolic antagonists. 14. The method of claim 13, wherein said peptide growth factor is selected from the group consisting of IGF (1,2), PDGF (AA, AB, BB), BMPs, FGF (1-20), TGF-beta (1-3), aFGF, bFGF, EGF, VEGF, parathyroid hormone (PTH), and parathyroid hormone-related protein (PTHrP). 15. The method of claim 13, wherein said anti-inflammatory factor is selected from the group consisting of anti-TNF.alpha., soluble TNF receptors, ILlra, soluble IL1 receptors, IL4, IL-10, and IL-13. 16. The method of claim 13, wherein said bone catabolic antagonist is selected from the group consisting of bisphosphonates, osteoprotegerin, and statins. 17. The method of claim 1, further comprising treating said patient with at least one procedure selected from the group consisting of bone autograft, bone allograft, autologous stem cell treatment, allogeneic stem cell treatment, electrical stimulation, internal fixation, external fixation and treatment with a bioactive bone agent selected from the group consisting of IGF (1,2), PDGF (AA, AB, BB), BMPs, FGF (1-20), TGF-beta (1-3), aFGF, bFGF, EGF, VEGF, parathyroid hormone (PTH), and parathyroid hormone-related protein (PTHrP), anti-inflammatory factors such as anti-TNF.alpha., soluble TNF receptors, Mira, soluble IL1 receptors, IL4, IL-10, and IL-13, pro-inflammatory factors, inhibitors of apoptosis, MMP inhibitors and bone catabolic antagonists such as bisphosphonates, osteoprotegerin, and statins. 18. The method of claim 1, wherein said patient is afflicted with a bone condition selected from the group consisting of bone fractures and segmental defects. 19. A bone implant comprising insulin and a pharmaceutically acceptable carrier, wherein said device is adapted for localized administration of insulin to a patient in need thereof. 20. The bone implant of claim 19, wherein said carrier is comprises poly-lactic acid, poly-glycolic acid, copolymers of poly-lactic acid or poly-glycolic acid. 21. The bone implant of claim 19, wherein said carrier comprises at least one bioerodible fatty acid or a metal salt of a fatty acid. 22. The bone implant of claim 19, wherein said fatty acid is selected from the group consisting of palmitic acid, steric acid, oleic acid, myristic acid, and metal salts thereof. 23. The bone implant of claim 19, wherein said carrier comprises porous or non-porous calcium phosphate, porous or non-porous hydroxyapatite, porous or non-porous tricalcium phosphate, porous or non-porous tetracalcium phosphate, porous or non-porous calcium sulfate, or a combination thereof.

Details for Patent 7,763,582

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	04/20/2000		2026-02-21
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	04/25/2007		2026-02-21
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2026-02-21